EU antitrust regulators have asked pharma rivals and customers for feedback in four business areas in light of Novo Holdings' ...

millaf – stock.adobe.com Ozempic is part of a class of diabetes and obesity drugs that mimic the GLP-1 hormone the body ...

Novo Nordisk reported forecast-beating third-quarter sales of its popular Wegovy weight-loss drug on Wednesday, reassuring ...

Excitement is building around a new weight loss drug, CagriSema, which is expected to surpass the effects of popular drugs ...

A mixed sales report for Novo Nordisk’s GLP-1 megablockbuster drugs failed to quiet concerns Wednesday that investors may ...

Are you a print subscriber? Activate your account. By Garett Sloane - 3 min 8 sec ago By Ewan Larkin - 8 min 31 sec ago By ...

Sales of Novo Nordisk’s (NVO) blockbuster weight loss drug Wegovy continue to soar, surpassing Wall Street expectations. The ...

The company narrowed its full-year guidance as its blockbuster weight-loss drug soars in popularity.

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion sales in 2023, it shows no signs ...

The drugmaker hopes to show CagriSema leads to at least 25% weight loss, without increased side effects. Its lead in a ...

Drugs Ozempic and Wegovy have slimmed down Hollywood stars — and millions of non-celebrities worldwide— while adding great ...